Neovascular Age-Related Macular Degeneration Treatment Market Report and Forecast 2024-2032

Neovascular Age-Related Macular Degeneration Treatment Market Outlook

The neovascular age-related macular degeneration treatment market size was valued at USD 11 billion in 2023 in the 7 major markets, driven by the increasing advancements in treatment technologies for neovascular AMD across the globe. The market size is anticipated to grow at a CAGR of 7.5% during the forecast period of 2024-2032 to achieve a value of USD 21.1 billion by 2032.

Neovascular Age-Related Macular Degeneration Treatment: Introduction

Neovascular age-related macular degeneration (AMD) treatment are the several therapeutic interventions and strategies that target the progression management this specific form of AMD. Neovascular AMD, also known as wet AMD, is recognized as the growth of abnormal blood vessels beneath the macula, which can lead to severe vision loss if left untreated. The primary purpose of treatment is to slow down or prevent further vision loss and preserve visual function in the patient. The use of anti-vascular endothelial growth factor (anti-VEGF) medications is the most common and effective treatment approach for neovascular AMD. These medications are administered through injections into the eye. These medicines block the growth of abnormal blood vessels and reduce leakage and inflammation in the retina. Examples of anti-VEGF drugs used in neovascular AMD treatment include ranibizumab, aflibercept, and bevacizumab. 

Neovascular Age-Related Macular Degeneration Treatment Market Analysis

The increasing prevalence of neovascular AMD globally is mainly due to the geriatric population. With rise in geriatric population, increase in demand for effective treatments for neovascular AMD is expected to increase as well. The market is encountering continuous technological advancements in treatment modalities for neovascular AMD and these advancements are expected to continue in coming years as well contributing to the neovascular age-related macular degeneration treatment market growth. The market expansion is being further fueled by the continuing research and development projects being made to increase treatment efficacy, decrease treatment frequency, and investigate alternative therapies.

With increasing awareness of the genetic and molecular factors contributing to neovascular AMD, there is a substantial shift towards personalized medicine across the 7 major markets. Targeted therapies and genetic testing are being explored to identify subgroups of patients who may respond better to specific treatments, allowing for more tailored and effective management accelerating the market growth.

Additionally, the integration of digital technologies, such as telemedicine and remote monitoring into neovascular AMD management is being increasing, further contributing to the market growth. Remote monitoring of disease progression and treatment response allows for more efficient patient management, reduces the need for frequent hospital visits, and enhances patient care.

Neovascular Age-Related Macular Degeneration Treatment Market Segmentations

Market Breakup by Drug Type

• Ranibizumab 

• Aflibercept 

• Bevacizumab 

• Brolucizumab 

• Faricimab 

• Others 

Market Breakup by Disease Type

• Dry AMD 

• Wet AMD 

Market Breakup by Age Group

• Less Than 60 

• Between 60 to 80 

• More Than 80 

Market by Disease Stage

• Early-Stage AMD 

• Intermediate Stage AMD 

• Late-Stage AMD  

Market by Gender

• Male 

• Female 

Market by Distribution Channel 

• Hospital Pharmacy 

• Retail Pharmacy 

• Online Pharmacy 

Market Breakup by Region- 7MM

• United States 

• EU-4 and the United Kingdom 
  • Germany  
  • France     
  • Italy 
  • Spain 
  • United Kingdom 

• Japan

Neovascular Age-Related Macular Degeneration Treatment Market Overview

The global population is aging, and advanced age is a significant risk factor for neovascular AMD. As the geriatric population continues to grow, the demand for neovascular AMD treatments is expected to increase, furth driving the neovascular age-related macular degeneration treatment market growth. The prevalence of neovascular AMD is also on the rise due to factors such as increasing life expectancy and lifestyle changes among people globally. The rising number of neovascular AMD patients is creating a substantial market demand for effective treatments contributing to the market growth. There have been multiple campaigns to increase awareness against AMD, patient education initiatives, and neovascular AMD screening programs which are substantially improving early detection rates as people. For quick action and the best possible treatment options, neovascular AMD must be identified early and accurately diagnosed. Furthermore, improvements in imaging methods like optical coherence tomography (OCT) and fluorescein angiography are enabling better neovascular AMD diagnosis and monitoring, which is further fuelling the market's need for related treatment choices internationally.

Neovascular Age-Related Macular Degeneration Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• F. Hoffmann-La Roche Ltd 

• Bausch & Lomb  

• Novartis AG 

• Pfizer, Inc. 

• AbbVie Inc. 

• Santen Pharmaceutical Co., Ltd. 

• Ophthotech Corporation 

• Alimera Sciences 

• GSK plc. 

• Bayer AG

Key Highlights of the Report